Radiotherapy in Italy for non-small cell lung cancer: Patterns of care survey

Tumori

Volumn 98, Issue 1, 2012, Pages 66-78

  Ramella, Sara ^a   Maranzano, Ernesto ^b   Frata, Paolo ^c   Mantovani, Cristina ^d   Lazzari, Grazia ^e   Menichelli, Claudia ^f   Navarria, Piera ^g   Pergolizzi, Stefano ^h   Salvi, Fabrizio ⁱ  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b S MARIA HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h San Vincenzo Hospital   (Italy)

ⁱ BELLARIA HOSPITAL   (Italy)

Author keywords

Lung cancer; Radiotherapy; Survey

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CONTROLLED STUDY; HEALTH SURVEY; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; STEREOTACTIC TREATMENT; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; ADULT; AGED; CANCER CENTER; CHEMORADIOTHERAPY; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE SURVEY; HEART; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RADIATION EXPOSURE; STATISTICS; STEREOTACTIC PROCEDURE;

ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DOSE FRACTIONATION; EVIDENCE-BASED MEDICINE; FEMALE; FLUORODEOXYGLUCOSE F18; HEALTH CARE SURVEYS; HEART; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; QUESTIONNAIRES; RADIOPHARMACEUTICALS; STEREOTAXIC TECHNIQUES;

EID: 84863204778     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800109     Document Type: Article

References (97)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin, 55: 74-108, 2005.
2. Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M, Graham M, Ettinger D, Johnstone D, Abrams R, Munden R, Starkschall G, Owen J: Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol, 21: 4553-4559, 2003. (Pubitemid 46594026)
3. Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF: Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer, 48: 93-102, 2005. (Pubitemid 40381004)
4. Kepka L, Danilova V, Saghatelyan T: Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: Results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer, 56: 235-245, 2007. (Pubitemid 46591989)
5. Palazzi M, Valdagni R, Poli M, Buffoli A, Leoni M, Vavassori V, Di Lorenzo I, Corbella F, Nava S, Cazzaniga LF: The role of radiotherapy in the treatment of stage III NSCLC: a survey of clinical practice in Lombardy, Italy, by the AIRO-Lombardia Cooperative Group. Tumori, 80: 286-289, 1994. (Pubitemid 24339852)
6. Aristei C, Amichetti M, Ciocca M: Radiotherapy in Italy after conservative treatment of early breast cancer. A survey by the Italian Society of Radiation Oncology (AIRO). Tumori, 94: 333-334, 2008.
7. Frata P, Ponticelli P, Cosentino D, Buffoli A, Di Pilla A, Morrica B, Palazzi M: Radiotherapy resources for the care of head and neck patients in Italy. A survey by the head and neck group of the Italian Association for Radiation Oncology (AIRO). Tumori, 94: 59-64, 2008. (Pubitemid 351487186)
8. I Tumori in Italia. Portale di epidemiologia oncologica, http://www.tumori.net/it
9. Reparto Epidemiologia dei Tumori del Centro Nazionale di Epidemiologia Sorveglianza e Promozione della Salute dell'Istituto Superiore di Sanità; http://www.iss.it/esps/stru/cont.php?id=11&lang=1&tipo=3
10. Delaney G, Barton M, Jacob S, Jalaludin B: A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol, 4: 120-128, 2003. (Pubitemid 36193172)
11. Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ: Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys, 49: 973-985, 2001. (Pubitemid 32184604)
12. Alexanian A, Torri V: Survey on the treatment of non-smallcell lung cancer in Italy. Ann Oncol, 11: 807-813, 2000.
13. Choy H, Yu S, Cmelak AJ, Mohr PJ, Johnson DH: Patterns of practice survey for non-small cell lung carcinoma in the US. Cancer, 88: 1336-1346, 2000. (Pubitemid 30155169)
14. Van Tinteren H, Hoekstra OS, Smit EF: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet, 359: 1388-1392, 2002. (Pubitemid 34442379)
15. Steenbakkers RJHM, Duppen JC, Fitton I: Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: A 'Big Brother' evaluation. Radiother Oncol, 77: 182-190, 2005. (Pubitemid 41682385)
16. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet, 352: 257-263, 1998.
17. Trodella L, Granone P, Valente S, Valentini V, Balducci M, Mantini G, Turriziani A, Margaritora S, Cesario A, Ramella S, Corbo GM, D'Angelillo RM, Fontana A, Galetta D, Cellini N: Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol, 62: 11-19, 2002. (Pubitemid 34121945)
18. Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E: Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for highrisk resected non-small cell lung cancer. J Clin Oncol, 19: 3912-3917, 2001. (Pubitemid 32912018)
19. Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA; Adjuvant Navelbine International Trialist Association: Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys, 72: 695-701, 2008.
20. Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M, Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer - Lung Cancer Cooperative Group Investigators: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst, 95: 1453-1461, 2003.
21. Scotti V, Meattini I, Saieva C, Agresti B, de Luca Cardillo C, Bastiani P, Livi L, Mangoni M, Di Cataldo V, Marrazzo L, Rampini A, Cipressi S, Bruni A, Santini P, Biti G: Post-operative radiotherapy in N2 non-small cell lung cancer: a retrospective analysis of 175 patients. Radiother Oncol, 96: 84-88, 2010.
22. Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, Yin WB: A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys, 47: 925-929, 2000. (Pubitemid 30345589)
23. Gauger J, Patz EF Jr, Coleman RE, Herndon JE 2nd : Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol, 2: 499-505, 2007. (Pubitemid 47171803)
24. Westeel V, Choma D, Clément F, Woronoff-Lemsi MC, Pugin JF, Dubiez A, Depierre A: Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg, 70: 1185-1190, 2000.
25. Kenny PM, King MT, Viney RC, Boyer MJ, Pollicino CA, McLean JM, Fulham MJ, McCaughan BC: Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J Clin Oncol, 26: 233-241, 2008.
26. Taylor NA, Liao ZX, Stevens C, Walsh G, Roth J, Putnam J Jr, Fossella F, Allen P, Cox JD, Komaki R: Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Int J Radiat Oncol Biol Phys, 56: 616-625, 2003. (Pubitemid 36677353)
27. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, Pairolero PC, Allen MS, Shaw EG, Marks RS, Frytak S, Lange CM, Li H: The impact of surgical adjuvant thoracic radiation therapy for patients with non-small cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer, 80: 1399-1408, 1997. (Pubitemid 27441013)
28. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD: Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol, 24: 2998-3006, 2006. (Pubitemid 46638932)
29. Munro AJ: What now for postoperative radiotherapy for lung cancer? Lancet, 352: 250-251, 1998.
30. Bonner JA, Spencer SA: Postoperative radiotherapy in non-small- cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy. J Clin Oncol, 24: 2978-2980, 2006. (Pubitemid 46638927)
31. Granone P, Keller S, Trodella L, Cesario A, Margaritora S, Porziella V, Valente S, Corbo GM, d'Angelillo R: Postoperative radiotherapy in completely resected, early-stage, non-small-cell lung cancer: reflections and future directions. Lung Cancer, 3: 589-591, 2002. (Pubitemid 35174675)
32. Burdett S, Stewart L: PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer, 47: 81-83, 2005. (Pubitemid 39643244)
33. Govindan R, Bogart J, Vokes EE: Locally advanced nonsmall cell lung cancer: the past, present, and future. J Thorac Oncol, 3: 917-928, 2008.
34. D'Addario G, Felip E: On behalf of the ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical. Recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19 (Suppl 2): ii39-ii40, 2008.
35. Grunenwald DH, Andre F, Le Pechoux C, Girard P, Lamer C, Laplanche A, Tarayre M, Arriagada R, Le Chevalier T: Benefit of surgery after hemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg, 122: 796-802, 2001.
36. Galetta D, Cesario A, Margaritora S, Porziella V, Macid G, D'Angelillo RM, Trodella L, Sterzi S, Granone P: Enduring challenge in the treatment of non-small cell lung cancer with clinical stage IIIB: results of a trimodality approach. Ann Thorac Surg, 76: 1802-1808, 2003.
37. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weik JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small- cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol, 13: 1880-1892, 1995.
38. Trodella L, Granone P, Valente S, Margaritora S, Macis G, Cesario A, D'Angelillo RM, Valentini V, Corbo GM, Porziella V, Ramella S, Tonini G, Galetta D, Ciresa M, Vincenzi B, Cellini N: Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol, 15: 389-398, 2004. (Pubitemid 38444541)
39. Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffé P, Von Briel C, Krueger T, Ris HB: Comparison of neoadjuvant cisplatin- based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg, 27: 1092-1098, 2005. (Pubitemid 40719592)
40. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet, 1: 379-386, 2009.
41. Uy KL, Darling G, Xu W, Yi QL, De Perrot M, Pierre AF, Waddell TK, Johnston MR, Bezjak A, Shepherd FA, Keshavjee S: Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg, 134: 188-193, 2007. (Pubitemid 46962027)
42. Park BB, Park JO, Kim H, Ahn YC, Choi YS, Kim K, Kim J, Shim YM, Ahn JS, Park K: Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer, 53: 323-330, 2006. (Pubitemid 44189567)
43. Kuten A, Anacak Y, Abdah-Bortnyak R, Chetver L, Zen Al Deen I, Daoud K, Nijem R, Billan S, Best L: Neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin and followed by surgery in locally advanced non-small-cell lung cancer. Am J Clin Oncol, 26: 184-187, 2003. (Pubitemid 36443564)
44. Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Janne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT: Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res, 9: 1698-1704, 2003. (Pubitemid 36554593)
45. Maas KW, Phernambucq EC, Sharouni SY, Stigt JA, Groen HJ, van den Borne BE, Senan S, Paul RM, Smit EF, Schramel FM: A phase II study of weekly docetaxel/cisplatin and concurrent radiotherapy followed by surgery in patients with stage III non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO 2007, Annu Meet Proc, 25 (Suppl 18): 18050 (abstract), 2005.
46. D'Angelillo RM, Trodella L, Ciresa M: Multimodality Treatment of stage III non-small cell lung cancer analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol, 4: 1517-1523, 2009.
47. O'Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F: Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev, 2010.
48. Aupèrin A, Le Péchoux C, Rolland E, Curran VJ, Furuse K, Fournel P, Balderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Vitterhoeeve A, Wang Xiaofei, Stewart L, Arriagada R, Burdett S, Pignon JP: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 28: 2181-2190, 2010.
49. Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 25: 1698-1704, 2007. (Pubitemid 46797950)
50. Kim S, Kim M, Choi E, Sohn H, Lee D, Suh C, Lee J, Yang H, Hong J, Kim W: Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 7528, 2007.
51. Krause M, Zips D, Thames HD, Kummermehr J, Baumann M: Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol, 80: 112-122, 2006. (Pubitemid 44314014)
52. Withers HR, Haustermans K: Where next with preoperative radiation therapy for rectal cancer? Int J Radiat Oncol Biol Phys, 58: 597-602, 2004. (Pubitemid 38142488)
53. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG: Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-smallcell lung cancer: a dose-escalation phase I trial. J Clin Oncol, 22: 4341-4350, 2004. (Pubitemid 41185154)
54. Vergnenègre A, Daniel C, Léna H, Fournel P, Kleisbauer JP, Le Caer H, Letreut J, Paillotin D, Pérol M, Bouchaert E, Preux PM, Robinet G; Groupe Francais de Pneumo-Cancerologie: Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-smallcell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). Lung Cancer, 47: 395-404, 2005. (Pubitemid 40248744)
55. Trodella L, De Marinis F, D'Angelillo RM, Ramella S, Cesario A, Valente S, Nelli F, Migliorino MR, Margaritora S, Corbo GM, Porziella V, Ciresa M, Cellini F, Bonassi S, Russo P, Cortesi E, Granone P: Induction cisplatin-gemcitabinepaclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. Lung Cancer, 54: 331-338, 2006. (Pubitemid 44637201)
56. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group; US Oncology: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol, 26: 5755-5760, 2008.
57. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M: Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 J Clin Oncol, 28: 3739-3745, 2010.
58. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol, 28: 3299-3306, 2010.
59. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V; Radiotherapy Group of European Organization for Research and Treatment of Cancer: Literature-based recommendations for treatment planning and execution in highdose radiotherapy for lung cancer. Radiother Oncol, 71: 139-146, 2004. (Pubitemid 38521181)
60. Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J: The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer, 41: 207-214, 2003. (Pubitemid 36842784)
61. Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA: Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys, 50: 681-685, 2001. (Pubitemid 32519597)
62. Hayman JA, Martel MK, Ten Haken RK, Normolle DP, Todd RF 3rd, Littles JF, Sullivan MA, Possert PW, Turrisi AT, Lichter AS: Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol, 19: 127-136, 2001. (Pubitemid 32063489)
63. Krol AD, Aussems P, Noordijk EM, Hermans J, Leer JW: Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? J Radiat Oncol Biol Phys, 34: 297-302, 1996. (Pubitemid 26031573)
64. Senan S, Bergers Sjaak, Samson JM: Can elective nodal irradiation be omitted in stage III non-small cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved- field radiotherapy. Int J Radiat Oncol Biol Phys, 54: 999-1006, 2002. (Pubitemid 35299439)
65. Balderbos J SA, De Jaeger K: First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy, Radiother Oncol, 66: 119-126, 2003.
66. Fernandes A, Faerber J, Finlay J: Clinical outcomes of ENI compared with involved field radiotherapy (IFRT) in NSCLC. J Clin Oncol, 27: 15s, (suppl; abstr 7541), 2009.
67. Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, Brown GS, Concannon J, Rotman M, Seydel HG: A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer, 45: 2744-2753, 1980. (Pubitemid 10063330)
68. Anderson CS, Curran W: Combined modality therapy for stage III NSCLC. Semin Radiat Oncol, 20: 186-191, 2010.
69. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20: 1335-1343, 2002. (Pubitemid 34182817)
70. Rosenman JG, Halle JS, Socinski MA, Deschesne K, Moore DT, Johnson H, Fraser R, Morris DE: High-dose conformal radiotherapy for treatment of stage IIIA/B non-small cell lung cancer: Technical issues and results for a phase I/II trial. Int J Radiat Oncol Biol Phys, 54: 348-356, 2002. (Pubitemid 35286797)
71. Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H: Phase I results of RTOG 0117: A phase I/II dose intensification study using 3D-CRT and concurrent chemotherapy for patients with inoperable non-small cell lung cancer. J Clin Oncol, 23: 7063, 2005.
72. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J: Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 65: 1106-1111, 2006.
73. Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC: Dose escalating conformal thoracic radiation therapy with induction concurrent carboplatin/paclitaxel in unresectable stage IIIa and IIIb non-small cell lung cancer: A modified phase I/II trial. Cancer, 92: 1213-1223, 2001.
74. Han K, Bezjak A, Xu W, Kane G: Has the practice of radiation oncology for locally advanced and metastatic non-small- cell lung cancer changed in Canada? Curr Oncol, 17: 33-40, 2010.
75. Fairchild A, Goh P, Sinclair E, Barnes EA, Ghosh S, Danjoux C, Barbera L, Tsao M, Chow E: Has the pattern of practice in the prescription of radiotherapy for the palliation of thoracic symptoms changed between 1999 and 2006 at the rapid response radiotherapy program? Int J Radiat Oncol Biol Phys, 70: 693-700, 2008. (Pubitemid 351199731)
76. Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J: Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer - a systematic review. Radiother Oncol, 71: 127-138, 2004. (Pubitemid 38521180)
77. Ramella S, Trodella L, Mineo TC, Pompeo E, Stimato G, Gaudino D, Valentini V, Cellini F, Ciresa M, Fiore M, Piermattei A, Russo P, Cesario A, D'Angelillo RM: Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. Int J Radiat Oncol Biol Phys, 76: 110-115, 2010.
78. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, Kado T, Takada Y: Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys, 55: 110-115, 2003. (Pubitemid 36020349)
79. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys, 45: 323-329, 1999. (Pubitemid 29408545)
80. Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, Lind PA: Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys, 51: 650-659, 2001.
81. Armstrong JC: Target volume definition in 3D conformal radiation therapy of lung cancer. Br J Radiol, 71: 587-594, 1998.
82. Mehta V: Radiation pneumonitis and pulmonary fibrosis in NSCLC: pulmonary function, prediction and prevention. Int J Radiat Oncol Biol Phys, 63: 5-24, 2005.
83. Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB: Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys, 76 (3 Suppl): S86-93, 2010.
84. Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, Marks LB: Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys, 76 (Suppl 3): S77-85, 2010. Review.
85. Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K, Lagramge JL, Le Pechoux C, Bernard L, Chastang C: A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer, 86: 265-273, 1999. (Pubitemid 29327583)
86. Lally BE, Detterbeck FC, Geiger AM, Thomas CR Jr, Machtay M, Miller AA, Wilson LD, Oaks TE, Petty WJ, Robbins ME, Blackstock AW: The risk of death from heart disease in patients with non small cell lung cancer who receive postoperative radiotherapy. Analysis of the Surveillance, Epidemiology, and End Results Database. Cancer, 110: 911-917, 2007. (Pubitemid 47257671)
87. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE: Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys, 76 (Suppl 3): S42-49, 2010.
88. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006.
89. Carey SM, Katz A, Constine LS: Stereotactic body radiation therapy for extracranial oligometastases: Does the sword have a double edge? Semin Radiat Oncol, 16: 67-76, 2006.
90. Brock J, Ashley S, Bedford J, Nioutsikou E, Partridge M, Brada M: Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol R Coll Radiol, 20: 666-676, 2008.
91. Grills IS, Hope AJ, Guckenberger M, Kestin L, Werner- Wasik M, Yan D, Sonke J, Bissonnette J, Xiao Y, Belderbos J: A multinational pooled analysis of 434 cases of stage I nonsmall cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative Lung Research Group. J Clin Oncol, 28: 15s, (suppl; abstr 7015), 2010.
92. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin LL: Outcomes after stereotactic lung radiotherapy or wedge resection for stage I NSCLC. J Clin Oncol, 28: 928-936, 2010.
93. Altorki NK: Stereotactic Body radiation therapy versus wedge resection for medically inoperable stage I lung cancer: tailored therapy or one size fits all? J Clin Oncol, 28: 905-907, 2010.
94. Timmermann RD: Surgery versus stereotactic body radiation therapy for early stage lung cancer: Who's down for the count? J Clin Oncol, 28: 907-909, 2010.
95. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA; American Society for Therapeutic Radiology and Oncology; American College of Radiology: American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys, 76: 326-332, 2010.
96. Buyyounouski MK, Balter P, Lewis B, D'ambrosio DJ, Dilling TJ, Miller RC, Schefter T, Tomé W, Harris Eleanor ER, Price RA Jr, Konski AA, Wallner PE: Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: Report of the ASTRO Emerging Technology Committee. Int J Radiat Oncol Biol Phys, 78: 3-10, 2010.
97. van der Voort van Zyp NC, Prévost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, Levendag PC, Nuyttens JJ: Quality of life after stereotactic radiotherapy for stage I non-small-cell lunger cancer. Int J Radiat Oncol Biol Phys, 77: 31-37, 2010.